Search clinical trials for: Envafolimab(immune checkpoint inhibitor anti-PD-L1 antibody)

Total 133086 results

University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.

Active, not recruiting

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer

United States, Canada
University Medical Center Groningen

Active, not recruiting

MPDL3280A-imaging-IST-UMCG

Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Netherlands
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Recurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant Tumors

China
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital

Recruiting

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Hepatocellular Carcinoma

China
Regeneron Pharmaceuticals

Terminated

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Advanced PD-L1 Positive Malignancies

United States
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)

PD-L1-selected Solid Tumors

Korea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Eastern Hepatobiliary Surgery Hospital

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Maastricht Radiation Oncology
Maastricht University Medical Center; Zuyderland Medical Centre

Completed

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Stage IV Non-small Cell Lung Cancer

Netherlands
The First Affiliated Hospital of Zhengzhou University

Recruiting

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Esophageal Neoplasms

China
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Active, not recruiting

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer (R-IMMUNE)

Rectal Neoplasms

Belgium
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Chinese PLA General Hospital

Recruiting

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Pancreatic Cancer | Biliary Tract Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Cervical Cancer | Advanced Solid Tumor

China
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Bladder Cancer

United States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Zhongnan Hospital

Recruiting

Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Bladder Cancer

United States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
Oncovir, Inc.
Chevy Chase Healthcare, Chevy Chase MD; Mt. Sinai School of Medicine, New York... and other collaborators

Terminated

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Solid Cancer

United States
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Baodong Qin

Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Chemotherapy | Immunotherapy | PD-L1

China
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
Groupe Hospitalier Pitie-Salpetriere
Vanderbilt University Medical Center; Vanderbilt University; Institute of Cardiometabolism...

Completed

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions (RAFALE)

Myocarditis | Cardiac Complication

France
ETOP IBCSG Partners Foundation
GlaxoSmithKline; Development Limited

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)

SCLC,Extensive Stage | SLFN11-positive

Switzerland, France, Spain, Italy
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Consorzio Oncotech

Completed

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study (ARIES)

Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Baodong Qin

Unknown

Effect of Chemotherapy on TMB in NSCLC

Chemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 Inhibitor

China
Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
Peking Union Medical College Hospital

Recruiting

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Hepatocellular Carcinoma

China
Immunobrain Checkpoint
National Institute on Aging (NIA); Alzheimer's Association

Recruiting

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Alzheimer's Disease

Israel, United Kingdom, Netherlands

Search clinical trials for: Envafolimab(immune checkpoint inhibitor anti-PD-L1 antibody)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations